Research programme: bacterial biofilm therapies - Caliper Life Sciences/Deinove
Latest Information Update: 07 Feb 2019
Price :
$50 *
At a glance
- Originator Caliper Life Sciences; Morphochem AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 07 Feb 2017 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 09 Aug 2006 Xenogen Corporation has been acquired and merged into Caliper Life Sciences
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG